Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human CCM2 Anticorps:
anti-Mouse (Murine) CCM2 Anticorps:
anti-Rat (Rattus) CCM2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal CCM2 Primary Antibody pour ELISA, WB - ABIN251695
Zawistowski, Stalheim, Uhlik, Abell, Ancrile, Johnson, Marchuk: CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. dans Human molecular genetics 2005
Human Polyclonal CCM2 Primary Antibody pour IHC, IHC (p) - ABIN4288902
Marchi, Corricelli, Trapani, Bravi, Pittaro, Delle Monache, Ferroni, Patergnani, Missiroli, Goitre, Trabalzini, Rimessi, Giorgi, Zavan, Cassoni, Dejana, Retta, Pinton: Defective autophagy is a key feature of cerebral cavernous malformations. dans EMBO molecular medicine 2015
A novel missense mutation in CCM2 were detected in cerebral cavernous malformations patient. Several CCM2 gene polymorphisms in sporadic CCM patients were reported.
Data suggest that signaling via ANP (Montrer NPPA Anticorps)/ANPR (atrial natriuretic factor/ANP (Montrer NPPA Anticorps) receptor (Montrer PPP5C Anticorps)) in vascular endothelial cells activates PAK4 (p21-activated kinase 4 (Montrer PAK4 Anticorps)) and CCM2 (cerebral cavernous malformation 2 protein), resulting in phosphorylation of MLC (myosin light chain), cytoskeletal reorganization, and cell spreading; kinase homology domain of ANPRA (guanylyl cyclase-A (Montrer NPR1 Anticorps)) activates downstream targets of ANP (Montrer NPPA Anticorps)/ANPR signaling.
Studies suggest that the 3 proteins of the Cerebral Cavernous Malformations (CCM) complex KRIT1/CCM1 (Montrer KRIT1 Anticorps), CCM2/malcavernin and CCM3/PDCD10 (Montrer PDCD10 Anticorps) not only require one another for reciprocal stabilization, but also act as a platform for signal transduction.
a new mutation in MGC4607/CCM2 was identified in several family members with spinal and cutaneous angiomas.
both CCM2 and CCM3 (Montrer PDCD10 Anticorps) are required for normal endothelial cell network formation.
Data find that several disease-associated missense mutations in CCM2 have the potential to interrupt the KRIT1 (Montrer KRIT1 Anticorps)-CCM2 interaction by destabilizing the CCM2 PTB (Montrer PTBP1 Anticorps) domain and that a KRIT1 (Montrer KRIT1 Anticorps) mutation also disrupts this interaction
Prevalence, frequency and characterization of CCM1 (Montrer KRIT1 Anticorps), CCM2 and CCM3 (Montrer PDCD10 Anticorps) variants in cerebral cavernous malformation Spanish patients.
Cerebral cavernous malformation(CCM)s develop because of loss of heart of glass (HEG (Montrer HEG1 Anticorps))-independent CCM2 signaling in murine transgenic endothelium of central nervous system after birth.
DNA sequencing and deletion/duplication testing of the CCM1 (Montrer KRIT1 Anticorps), CCM2, and CCM3 (Montrer PDCD10 Anticorps) genes in the proband revealed a CCM1 (Montrer KRIT1 Anticorps) c.601CNG mutation.
CCM2 mutations are associated with cerebral cavernous malformation in some Japanese patients.
Loss of CCM2 is associated with Cerebral Cavernous Malformations.
CCM2 expression and it's role during ovary and testis development
CCM2:MEKK3 (Montrer MAP3K3 Anticorps)-mediated regulation of Rho-ROCK signalling is required for maintenance of neurovascular integrity, a mechanism by which CCM2 loss leads to disease.
Down-modulation of STK25 (Montrer STK25 Anticorps), but not STK24 (Montrer STK24 Anticorps), rescued medulloblastoma cells from NGF (Montrer NGFB Anticorps)-induced TrkA (Montrer NTRK1 Anticorps)-dependent cell death, suggesting that STK25 (Montrer STK25 Anticorps) is part of the death-signaling pathway initiated by TrkA (Montrer NTRK1 Anticorps) and CCM2.
The inducible deletion of Ccm2 in adult mice recapitulates the cerebral cavernous malformations-like brain lesions in humans.
Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice.
Rac1/osmosensing scaffold for MEKK3 contributes via phospholipase C (Montrer PLC Anticorps)-gamma1 to activation of the osmoprotective transcription factor NFAT5 (Montrer NFAT5 Anticorps).
Pdcd10 (Montrer PDCD10 Anticorps) has a different role in cerebral cavernous malformation than Ccm2 and Krit1 (Montrer KRIT1 Anticorps)
The KRIT1 (Montrer KRIT1 Anticorps)-CCM2 interaction regulates endothelial junctional stability and vascular barrier function by suppressing activation of the RhoA (Montrer RHOA Anticorps)/ROCK signaling pathway.
CCM1 (Montrer KRIT1 Anticorps) associates with CCM2, indicating that the genetic heterogeneity observed in familial cavernous malformation pathogenesis may reflect mutation of different molecular members of a coordinated signaling complex.
This gene encodes a scaffold protein that functions in the stress-activated p38 Mitogen-activated protein kinase (MAPK) signaling cascade. The protein interacts with SMAD specific E3 ubiquitin protein ligase 1 (also known as SMURF1) via a phosphotyrosine binding domain to promote RhoA degradation. The protein is required for normal cytoskeletal structure, cell-cell interactions, and lumen formation in endothelial cells. Mutations in this gene result in cerebral cavernous malformations. Multiple transcript variants encoding different isoforms have been found for this gene.
, cerebral cavernous malformation 2
, cerebral cavernous malformations 2 protein
, cerebral cavernous malformation 2 homolog
, cerebral cavernous malformations protein 2 homolog
, osmosensing scaffold for MEKK3